Douglas M. Hunt - 03 Jan 2023 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Signature
/s/ Chris Culotta as attorney-in-fact for Douglas M. Hunt
Issuer symbol
PBYI
Transactions as of
03 Jan 2023
Net transactions value
-$17,652
Form type
4
Filing time
05 Jan 2023, 16:33:11 UTC
Previous filing
06 Dec 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Sale $17,652 -4,225 -5.6% $4.18 71,350 03 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.1922, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.